Med Life (LTS:0RO5) YoY EBITDA Growth: -39.51% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RO5 Med Life SA LTS:0RO5
67 GF Score
Price lei11.62
GF Value lei1.42
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Med Life YoY EBITDA Growth?

Med Life LTS:0RO5 67 YoY EBITDA Growth is -39.51% as of Jun. 2026. GuruFocus rates LTS:0RO5 with a GF Score™ of 67/100 and a GF Value™ of lei1.42 (Significantly Overvalued). The stock has 5 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Med Life's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was -39.51%.

Med Life's EBITDA per Share for the three months ended in Jun. 2026 was lei0.12.

Med Life YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Med Life's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Med Life YoY EBITDA Growth Chart

Med Life Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 50.58 31.78 -12.75 18.65 38.26

Med Life Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.81 -16.00 12.09 21.39 -39.51
LTS:0RO5
67GF Score
Med Life SA LTS:0RO5
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Med Life YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Med Life's YoY EBITDA Growth for the fiscal year that ended in Dec. 2024 is calculated as:

YoY EBITDA Growth (A: Dec. 2024 )
=(EBITDA per Share (A: Dec. 2024 )-EBITDA per Share (A: Dec. 2023 ))/ | EBITDA per Share (A: Dec. 2023 ) |
=(0.73-0.528)/ | 0.528 |
=38.26 %

Med Life's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Mar. 2025 )) / | EBITDA per Share (Q: Mar. 2025 )) |
=(0.124-0.205)/ | 0.205 |
=-39.51 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -39.51% mean?
Med Life (LTS:0RO5) has a YoY EBITDA Growth of -39.51% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Med Life and its competitors.
Is Med Life's YoY EBITDA Growth too high?
Med Life's current YoY EBITDA Growth is -39.51%. Overall, Med Life has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Med Life's YoY EBITDA Growth compare to HCA and THC?
Med Life's YoY EBITDA Growth of -39.51% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Healthcare Providers & Services company?
A good YoY EBITDA Growth depends on the Healthcare Providers & Services industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Med Life and its competitors. Med Life's current YoY EBITDA Growth is -39.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Med Life stock overvalued right now?
Based on GuruFocus' analysis, Med Life (LTS:0RO5) is currently considered Significantly Overvalued. The stock's GF Value™ is lei1.42, compared to a current price of lei11.62 — trading 718.3% above its estimated fair value. The current YoY EBITDA Growth is -39.51%. Med Life's overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Med Life (LTS:0RO5), the current YoY EBITDA Growth is -39.51% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Med Life (LTS:0RO5) Overvalued in 2026?

Based on GuruFocus' analysis, Med Life stock appears to be overvalued. The current stock price of lei11.62 is trading 718.3% above its estimated GF Value™ of lei1.42. GuruFocus considers Med Life to be Significantly Overvalued.

Key valuation signals for LTS:0RO5:

  • YoY EBITDA Growth: -39.51%
  • GF Value™: lei1.42 vs. price of lei11.62 (718.3% above fair value)
  • GF Score™: 67/100 with 5 warning signs

No single metric tells the full story. See the LTS:0RO5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Med Life Business Description

Other Exchanges M:RomaniaO0C:Germany
Address Calea Grivitei, No. 365, District 1, Bucharest, ROU
Med Life SA is a healthcare provider in Romania. The Company's activity resides in the performance of healthcare services activities through medical centres with national coverage. It is engaged in the provision of rendering of medical services, rental of medical facilities and acquisition of materials and commodities. The company provides medical service through Hyper clinics in Arad, Bucharest, Braila, Brasov, Cluj, Constanta, Craiova, Galati, Iasi, Oradea, Ploiesti, Sibiu and Timisoara; Clinics, hospitals located in Bucharest, Arad, Sibiu, Brasov, Cluj and Ploiesti, Laboratories, Pharmacies and Dental Clinics.
67GF Score

Get the complete analysis for LTS:0RO5

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

lei11.62
Price
lei1.42
GF Value